TW201625268A - 包含阿茲海默症之治療劑的有關神經細胞之軸索功能不全之疾患之治療劑 - Google Patents

包含阿茲海默症之治療劑的有關神經細胞之軸索功能不全之疾患之治療劑 Download PDF

Info

Publication number
TW201625268A
TW201625268A TW104113201A TW104113201A TW201625268A TW 201625268 A TW201625268 A TW 201625268A TW 104113201 A TW104113201 A TW 104113201A TW 104113201 A TW104113201 A TW 104113201A TW 201625268 A TW201625268 A TW 201625268A
Authority
TW
Taiwan
Prior art keywords
group
diosgenin
cas
ene
oral administration
Prior art date
Application number
TW104113201A
Other languages
English (en)
Chinese (zh)
Inventor
東田千尋
松谷裕二
杉本健士
Original Assignee
瑞基里歐股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54332482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201625268(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞基里歐股份有限公司 filed Critical 瑞基里歐股份有限公司
Publication of TW201625268A publication Critical patent/TW201625268A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
TW104113201A 2014-04-25 2015-04-24 包含阿茲海默症之治療劑的有關神經細胞之軸索功能不全之疾患之治療劑 TW201625268A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014091718 2014-04-25
JP2014147890 2014-07-18

Publications (1)

Publication Number Publication Date
TW201625268A true TW201625268A (zh) 2016-07-16

Family

ID=54332482

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104113201A TW201625268A (zh) 2014-04-25 2015-04-24 包含阿茲海默症之治療劑的有關神經細胞之軸索功能不全之疾患之治療劑

Country Status (4)

Country Link
US (1) US20170129915A1 (OSRAM)
JP (2) JP6165323B2 (OSRAM)
TW (1) TW201625268A (OSRAM)
WO (1) WO2015163318A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259612A1 (zh) * 2019-06-26 2020-12-30 中国科学院上海药物研究所 一种抗抑郁甾体化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
BR112019024851A2 (pt) 2017-06-02 2020-06-09 Fujifilm Toyama Chemical Co Ltd agente para evitar ou tratar atrofia cerebral
US11666551B2 (en) 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
SG11201911515QA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating spinocerebellar ataxia
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (en) 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用
JP2025505820A (ja) * 2022-02-18 2025-02-28 ベイジン フィトベント ファーマシューティカル テクノロジー カンパニー,リミテッド サルササポゲニン構造に基づく誘導体およびその医薬組成物の使用
CN116621912A (zh) * 2022-02-18 2023-08-22 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途
CN114805286B (zh) * 2022-05-06 2023-06-16 深圳职业技术学院 一种萘并氧硫杂卓类衍生物的制备方法
JPWO2024024395A1 (OSRAM) * 2022-07-29 2024-02-01

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746930B2 (en) * 1998-04-24 2002-05-09 New Chapter IP Pty Ltd Therapeutic compositions
CA2479249A1 (en) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc. Neuroprotective spirostenol pharmaceutical compositions
JP2008516972A (ja) * 2004-10-14 2008-05-22 ジョージタウン ユニバーシティー 神経保護作用を有するスピロステノールの薬学的組成物
JP2007016013A (ja) * 2005-06-10 2007-01-25 Kanebo Cosmetics Inc 更年期の皮膚改善用経口組成物
US20090123575A1 (en) * 2007-11-12 2009-05-14 Thomas Lake Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses
JP2012031153A (ja) * 2010-06-29 2012-02-16 Takara Bio Inc 脂肪燃焼促進剤
WO2013149580A1 (en) * 2012-04-03 2013-10-10 Chiming Che Timosaponin compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259612A1 (zh) * 2019-06-26 2020-12-30 中国科学院上海药物研究所 一种抗抑郁甾体化合物

Also Published As

Publication number Publication date
JPWO2015163318A1 (ja) 2017-04-20
US20170129915A1 (en) 2017-05-11
JP2017165776A (ja) 2017-09-21
JP6165323B2 (ja) 2017-07-19
WO2015163318A1 (ja) 2015-10-29

Similar Documents

Publication Publication Date Title
JP6165323B2 (ja) アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
US10682354B2 (en) Compositions and methods
EP2086538B1 (en) Combination therapies for treating alzheimer's disease using dimebon and donepezil
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
US12329757B2 (en) Methods for increasing sepiapterin plasma exposure
TWI525092B (zh) Tetrahydrocarboline derivatives
CN104487429B (zh) 杂环黄酮衍生物、组合物及与其相关的方法
US20100130537A1 (en) Cinnamide compounds for dementia
EP2813498B1 (en) Compounds for Alzheimer's disease
JP2010540439A (ja) 神経保護性の及び認知を向上させる性質を備えた水素化されたピリド[4,3−b]インドール類のフッ素を含有する誘導体、調製するための工程、並びに使用
JP4989775B2 (ja) 脳機能改善作用を有するペプチド
US20150126464A1 (en) Therapeutic drug and therapeutic method for neurological diseases including alzheimer's disease associated with 1,25d3-marrs
KR20190111133A (ko) 전립선암 치료용 조합, 약학 조성물 및 치료 방법
WO2015024819A1 (en) V1a antagonists to treat phase shift sleep disorders
JP4421832B2 (ja) 記憶促進剤
JP2011519953A (ja) 注意欠陥障害および性機能不全の治療のための3−ヒドロキシジェピロン
WO2017074957A1 (en) Oxysterols and hedgehog signaling
JP2006513207A (ja) 行動障害の治療のためのイストラデフィリン(kw−6002)の使用
CN1247578C (zh) 含有2-芳基-8-氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
JP5728105B1 (ja) ヘンナ花部の新規成分
CN118591539A (zh) 经取代的噻唑烷二酮衍生物化合物及包含其的癌症的预防或治疗用药物组合物
HK1179476A (en) Methods and compositions for improving cognitive function
JP2011136930A (ja) 脳機能改善用組成物および脳機能を改善する方法